Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors

 

 Buy Article Permissions and Reprints

Summary

Clopidogrel is a prodrug that is converted via the hepatic cytochrome P450 system into its active thiol metabolite. Evidence is accumulating that proton pump inhibitors (PPIs) inhibit this enzymatic pathway and may therefore attenuate the antiplatelet effect of clopidogrel. The objective of this study was to investigate whether patients on clopidogrel therapy after drug-eluting stent (DES) placement who also receive a PPI are at higher risk of stent thrombosis (ST). This is a retrospective analysis of patients who received dual antiplatelet treatment including clopidogrel after DES placement. Outcomes were compared according to PPI therapy. The primary endpoint was the incidence of definite ST at 30 days. Secondary endpoints were death, combined death or ST and myocardial infarction (MI). The study population included 3,338 patients and 698 patients (20.9%) received PPIs. Patients receiving a PPI had a higher risk profile at baseline. Multivariate analysis showed that PPI treatment was not independently associated with the occurrence of ST [adjusted HR 1.8 (95% CI: 0.7–4.7), p=0.23] or MI [adjusted HR 1.3 (0.8–2.3), p=0.11]. PPI treatment was significantly associated with death [adjusted HR 2.2 (1.1–4.3), p=0.02] and death or ST [adjusted HR 3.3(1.7–6.7), p=0.02]. Concomitant treatment with a PPI in patients receiving dual antiplatelet treatment after coronary stenting is not an independent predictor of ST. The higher mortality is probably due to confounding as patients on PPIs had a higher risk profile at baseline.

• References

• 1 King 3rd SB, Smith Jr SC, Hirshfeld Jr JW. et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
  CrossrefPubMedGoogle Scholar
• 2 Nikolsky E, Mehran R, Lansky A. et al. Impact of Gastrointestinal Bleeding on Outcomes of Patients Treated With Contemporary Antithrombotic Strategies: Pooled Analysis From 3 Randomized Trials. American College of Cardiology 58th Annual Scientific Session and i2 Summit: Innovation in Intervention; 2009; Orlando, Florida. J Am Coll Cardiol 2009; 53 (Suppl. 051) A28.
  CrossrefPubMedGoogle Scholar
• 3 Bhatt DL, Scheiman J, Abraham NS. et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.
  CrossrefPubMedGoogle Scholar
• 4 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Hollopeter G, Jantzen HM, Vincent D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
  CrossrefPubMedGoogle Scholar
• 6 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
  CrossrefPubMedGoogle Scholar
• 7 Price MJ, Endemann S, Gollapudi RR. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
  CrossrefPubMedGoogle Scholar
• 8 Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
  CrossrefPubMedGoogle Scholar
• 9 Bonello L, Paganelli F, Arpin-Bornet M. et al. Vasodilator-stimulated phospho-protein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
  CrossrefPubMedGoogle Scholar
• 10 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
  CrossrefPubMedGoogle Scholar
• 11 Gurbel PA, Bliden KP, Guyer K. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
  CrossrefPubMedGoogle Scholar
• 12 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
  CrossrefPubMedGoogle Scholar
• 13 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
  CrossrefPubMedGoogle Scholar
• 14 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
  CrossrefPubMedGoogle Scholar
• 15 Gilard M, Arnaud B, Cornily JC. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
  CrossrefPubMedGoogle Scholar
• 16 Sibbing D, Morath T, Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Cuisset T, Frere C, Quilici J. et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54: 1149-1153.
  CrossrefPubMedGoogle Scholar
• 18 Siller-Matula JM, Spiel AO, Lang IM. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148e141-145.
  PubMedGoogle Scholar
• 19 Juurlink DN, Gomes T, Ko DT. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj 2009; 180: 713-718.
  CrossrefPubMedGoogle Scholar
• 20 Ho PM, Maddox TM, Wang L. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc 2009; 301: 937-944.
  CrossrefPubMedGoogle Scholar
• 21 O’Donoghue ML, Braunwald E, Antman EM. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
  CrossrefPubMedGoogle Scholar
• 22 Bhatt DL. COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. TCT Proceedings 2009; San Francisco, CA, 2009.
  PubMedGoogle Scholar
• 23 Food and Drug Aministration, Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). [Last accessed: November 22nd, 2009]; Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm
  PubMedGoogle Scholar
• 24 Schulz S, Schuster T, Mehilli J. et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4 year period. Eur Heart J 2009; 30: 2714-2721.
  CrossrefPubMedGoogle Scholar
• 25 Cutlip DE, Windecker S, Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
  CrossrefPubMedGoogle Scholar
• 26 The TIMI Study Group. Definitions Used In TIMI Trials. [Last accessed: November 2009]; Available from: http://www.timi.org.
  PubMedGoogle Scholar
• 27 Sibbing D, Stegherr J, Latz W. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
  PubMedGoogle Scholar
• 28 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
  CrossrefPubMedGoogle Scholar
• 29 Stanek EJ, Aubert RE, Flockhart DA. et al. A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. Society for Cardiovascular Angiography and Interventions 2009. Scientific Sessions; May, 6th 2009; Las Vegas, NV; 2009.
  PubMedGoogle Scholar
• 30 Dunn SP, Macaulay TE, Brennan DM. et al. Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial. Circulation 2008; 118: S815-S815.
  PubMedGoogle Scholar
• 31 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
  CrossrefPubMedGoogle Scholar
• 32 Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet 2009; 374: 952-954.
  CrossrefPubMedGoogle Scholar
• 33 Bhatt DL. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1), (NCT00557921). [Last accessed: November, 22nd 2009]; Available from: http://clinicaltrials.gov/ct2/show/NCT00557921?term=cogent&rank=1.
  PubMedGoogle Scholar
• 34 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
  CrossrefPubMedGoogle Scholar
• 35 Leon MB, Baim DS, Popma JJ. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671.
  CrossrefPubMedGoogle Scholar
• 36 Airoldi F, Colombo A, Morici N. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
  CrossrefPubMedGoogle Scholar
• 37 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
  CrossrefPubMedGoogle Scholar
• 38 ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis.. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999; 56: 347-379.
  PubMedGoogle Scholar